Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

Journal of Experimental Medicine

Volumn 186, Issue 8, 1997, Pages 1287-1298

  Ugolini, Sophie ^a   Mondor, Isabelle ^a   Parren, Paul W H I ^b   Burton, Dennis R ^b   Tilley, Shermaine A ^c   Klasse, Per Johan ^d   Sattentau, Quentin J ^a  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HLA DR ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; T LYMPHOCYTE; VIRION; VIRUS ADSORPTION; VIRUS NEUTRALIZATION;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; NEUTRALIZATION TESTS; RECEPTORS, VIRUS; SOLUBILITY;

EID: 0030726970     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.8.1287     Document Type: Article

References (73)

1. Dimmock, N.J. 1993. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183:1-149.
2. Dimmock, N.J. 1995. Update on the neutralization of animal viruses. Rev. Med. Virol. 5:165-179.
3. Iorio, R.M., R.L. Glickman, A.M. Riel, J.P. Sheenan, and M.A. Bratt. 1989. Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent attachment. Virus Res. 13:245-262.
4. Smith, T.J., N.H. Olson, R.H. Cheng, H. Liu, E.S. Chase, W.M. Lee, D. Leippe, A.G. Mosser, R.R. Rueckert, and T.S. Baker. 1993. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J. Virol. 67: 1148-1158.
5. Massey, R.J., and G. Schoetman. 1981. Topographical analysis of viral epitopes using monoclonal antibodies: mechanism of virus neutralization. Virology. 115:20-32.
6. Kennedy-Stoskopf, S., and O. Narayan. 1986. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence. J. Virol. 59:37-14.
7. McDougal, J.S., J.K.A. Nicholson, G.D. Cross, S.P. Cort, M.S. Kennedy, and A.C. Mawle. 1986. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformational dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J. Immunol. 137:2937-2944.
8. Sun, N.-C., D.D. Ho, C.R.Y. Sun, R.-S. Lion, W. Gordon, M.S.C. Fung, X.-L. Li, R.C. Ting, T.H. Lee, N.T. Chang, and T.-W. Chang. 1989. Generation and characterization ot monoclonal antibodies to the putative CD4-binding domain ot human immunodeficiency virus type 1 gp120. J. Virol. 63: 3579-3585.
9. Ho, D.D., J.C. Kaplan, I.E. Rackauskas, and M.E. Gurney. 1988. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science (Wash. DC). 239:1021-1023.
10. Posner, M.R., T. Hideshima, T. Cannon, M. Mukherjee, K.H. Mayer, and R.A. Byrn. 1991. An IgG human monoclonal antibody that reacts with HIV-1 gp120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146: 4325-4332.
11. Montefiori, D.C., B.S. Graham, J. Zhou, J. Zhou, R.A. Bucco, D.H. Schwartz, L.A. Cavacini, M.R. Posner, and the NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993. V3-spedfic neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site. J. Clin. Invest. 92:840-847.
12. Moore, J.P., and D.D. Ho. 1995. HIV neutralization: the consequence of viral adaptation to growth on transformed T cells. AIDS (Lond.). 9(Suppl. A):S117-S136.
13. Poignard, P., P.J. Klasse, and Q.J. Sattentau. 1996. Neutralization of the human immunodeficiency virus type 1. Immunol. Today. 17:239-246.
14. Sattentau, Q.J. 1996. Neutralization of HIV by antibody. CuRr. Opin. Immunol. 8:540-545.
15. Burton, D.R., and D.C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS (Lond.). 11(Suppl. A):S87-S98.
16. Chamat, S., P. Nara, L. Berquist, A. Whalley, W.J. Morrow, H. Kohler, and C.Y. Kang. 1992. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. J. Immunol. 149:649-654.
17. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
18. Trkola, A., A.B. Pomales, H. Yuan, B. Korber, P.J. Maddon, G.P. Allaway, H. Katinger, C.F. Barbas III, D. Burton, D.D. Ho, and J.P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
19. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
20. Moore, J.P., and J. Sodroski. 1996. Antibody cross competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
21. Linsley, P.S., J.A. Ledbetter, E. Kinney-Thomas, and S.-L. Hu. 1988. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J. Virol. 62:3695-3702.
22. + cells by monoclonal antibodies to gp110. AIDS (Lond.). 2:165-169.
23. Skinner, M.A., A.J. Langlois, C.B. McDanal, J.S. McDougal, D.P. Bolognesi, and T.J. Matthews. 1988. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 62:4195-4200.
24. Lu, S., S.D. Putney, and H.L. Robinson. 1992. Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. J. Virol. 66:2457-2550.
25. Pelchen-Matthews, A., P. Clapham, and M. Marsh. 1995. Role of CD4 endocytosis in human immunodeficiency virus infection. J. Virol. 69:8164-8168.
26. Armstrong, S.J., T.L. McInerney, L. McLain, B. Wahren, J. Hinkula, M. Levi, and N.J. Dimmock. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77:2931-2941.
27. Poignard, P., T. Fouts, D. Naniche, J.P. Moore, and Q.J. Sattentau. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183:473-484.
28. Trkola, A., T. Dragic, J. Arthos, J.M. Binley, W.C. Olson, G.P. Allaway, C. Cheng-Mayer, J. Robinson, P.J. Maddon, and J.P. Moore. 1996. CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (Lond.). 384:184-187.
29. Wu, L., N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (Lond.). 384:179-183.
30. Tilley, S.A., W.J. Honnen, M.E. Racho, M. Hilgartner, and A. Pinter. 1991. A human monoclonal antibody against the CD4-binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 142:247-259.
31. Thali, M., U. Olshevsky, C. Furman, D. Gabuzda, M. Posner, and J. Sodroski. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognised by a broadly reactive neutralising human monoclonal antibody. J. Virol. 65:6188-6193.
32. Earl, P.L., C.C. Broder, D. Long, S.A. Lee, J. Peterson, S. Chakrabarti, R.W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
33. Bou-Habib, D.C., G. Roderiquez, T. Oravecz, P.W. Berman, P. Lusso, and M.A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
34. Sattentau, Q.J., and J.P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
35. Moore, J.P., J.A. McKeating, W.A. Norton, and Q.J. Sattentau. 1991. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J. Virol. 65:1133-1140.
36. Moore, J.P., J.A. McKeating, Y. Huang, A. Ashkenazi, and D.D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralisation differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
37. Sattentau, Q.J., J.P. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:7383-7393.
38. + T cell clone (PM1): failure to downregulate CD4 and to interfere with cell line-tropic HIV-1. J. Virol. 69:3712-3720.
39. Fisher, A.G., B. Ensoli, D. Looney, A. Rose, R.C. Gallo, M.S. Saag, G.M. Shaw, B.H. Hahn, and F. Wong-Staal. 1988. Biologically diverse molecular variants within a single HIV-1 isolate. Nature (Lond.). 334:444-447.
40. + cells from virus binding. J. Exp. Med. 172: 1233-1242.
41. Kinley-Thomas, E., J.N. Weber, J. McClure, P.R. Clapham, M.C. Singhal, M.K. Shriver, and R.A. Weiss. 1988. Neutralizing monoclonal antibodies to the AIDS virus. AIDS (Lond.). 2:25-29.
42. McKeating, J.A., J. Cordell, C.J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology. 191:732-742.
43. Gorny, M.K., S. Conley, A. Karwowska, A. Buchbinder, J.-Y. Xu, E.A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
44. Conley, A.J., M.K. Gorny, J.A. Kessler, L.J. Boots, M. Ossorio-Castro, S. Koenig, D.W. Lineberger, E.A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
45. Warner, S.V., A. Pinter, W.J. Honnen, M. Girard, E. Muchmore, and S.A. Tilley. 1994. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognised by a highly potent, neutralizing chimpanzee monoclonal antibody. J. Virol. 68:4636-4642.
46. Thali, M., J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
47. Moore, J.P., A. Trkola, B. Korber, L.J. Boots, J.A. Kessler, F.E. McCutchan, J. Mascola, D.D. Ho, J. Robinson, and A.J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
48. Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, L.S. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, and D. Burton. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (Wash. DC). 266:1024-1027.
49. Burton, D.R., C.F.I. Barbas, M.A.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to HIV-1 from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-10137.
50. Barbas, C.F.I., E. Bjorling, F. Chiodi, F. Dunlop, D. Cababa, T.M. Jones, S.L. Zebedee, M.A.A. Persson, P.L. Nara, E. Norrby, and D. Burton. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA. 89:9339-9343.
51. Roben, P., J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas III, and D. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
52. Barbas, C.F.I., T.A. Collett, W. Amberg, P. Roben, J. Binley, D. Hoekstra, D. Cababa, T.M. Jones, R.A. Williamson, G.R. Pilkington, et al. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
53. Ditzel, H.J., P.W.H.I. Parren, J. Binley, J. Sodroski, J.P. Moore, C.F. Barbas, and D.R. Burton. 1997. Mapping the protein surface of HIV-1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267:684-689.
54. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
55. Fisher, R.A., J.M. Bertonis, W. Meier, V.A. Johnson, D.S. Costopoulos, T. Liu, R. Tizard, B.D. Walker, M.S. Hirsch, R.T. Schooley, et al. 1988. HIV infection is blocked in vitro by recombinant soluble CD4. Nature (Lond.). 331:76-78.
56. McKeating, J.A., A. McKnight, and J.P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralisation. J. Virol. 65:852-860.
57. Moore, J.P., J.A. McKeating, R.A. Weiss, and Q.J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (Wash. DC). 250:1139-1142.
58. Karber, G. 1931. Beitrag zur kollectiven Behandlung pharmacologoscher Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-487.
59. Gluschankof, P., I. Mondor, H.R. Gelderblom, and Q.J. Sattentau. 1997. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type 1 (HIV-1) preparations. Virology. 230:125-133.
60. Bess, J.W., R.J. Gorelick, L.E. Henderson, and L.O. Arthur. 1997. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology. 230: 134-144.
61. Sattentau, Q.J., and J.P. Moore. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoproteins by soluble CD4 binding. J. Exp. Med. 174:407-415.
62. Kennedy, M.S., S. Orloff, C.C. Ibegbu, C.D. Odell, P.J. Maddon, and J.S. McDougal. 1991. Analysis of synergism/ antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res. Hum. Retroviruses. 7:975-981.
63. Tilley, S.A., W.J. Honnen, M.E. Racho, T.-C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res. Hum. Retroviruses. 8:461-467.
64. Potts, B.J., K.G. Field, Y. Wu, M. Posner, L. Cavacini, and M. White-Scharfe. 1993. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology. 197:415-419.
65. Laal, S., S. Burda, M.K. Gorny, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001-4008.
66. Vijh-Warrier, S., A. Pinter, W.J. Honnen, and S.A. Tilley. 1996. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4 binding site. J. Virol. 70:4466-4473.
67. Klasse, P.J., and J.P. Moore. 1996. Quantitative model of antibody-and soluble CD4-mediated neutralization of primary isolates and T cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:3668-3677.
68. Kabat, D., S.L. Kozak, K. Wehrly, and B. Chesebro. 1994. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 68:2570-2577.
69. Kozak, S.L., E.J. Platt, N. Madani, F.E. Ferro, K. Peden, and D. Kabat. 1997. CD4, CXCR-4 and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71: 873-882.
70. McInerney, T.L., L. McLain, S.J. Armstrong, C.F. Barbas III, D.R. Burton, and N.J. Dimmock. 1997. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a post-fusion event. Virology. 233:313-326.
71. Srivastava, K.K., R. Fernandez-Larsson, D.M. Zinkus, and H.L. Robinson. 1991. Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness. J. Virol. 65: 3900-3902.
72. Demaria, S., and Y. Bushkin. 1996. Soluble CD4 induces the binding of human immunodeficiency virus type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41. AIDS Res. Hum. Retroviruses. 12:281-290.
73. Demaria, S., S.A. Tilley, A. Pinter, and Y. Bushkin. 1995. Bathophenanthroline disulfonate and soluble CD4 as probes for early events of HIV-1 entry. AIDS Res. Hum. Retroviruses. 11:127-139.